Compare · CNMD vs TMDX
CNMD vs TMDX
Side-by-side comparison of CONMED Corporation (CNMD) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNMD and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.56B, about 2.0x CNMD ($1.30B).
- Over the past year, CNMD is down 9.3% and TMDX is down 32.6% - CNMD leads by 23.3 points.
- CNMD has been more active in the news (9 items in the past 4 weeks vs 4 for TMDX).
- TMDX has more recent analyst coverage (18 ratings vs 16 for CNMD).
- Company
- CONMED Corporation
- TransMedics Group Inc.
- Price
- $43.21-4.01%
- $74.01-2.55%
- Market cap
- $1.30B
- $2.56B
- 1M return
- +25.25%
- -2.15%
- 1Y return
- -9.34%
- -32.60%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 1987
- 2019
- News (4w)
- 9
- 4
- Recent ratings
- 16
- 18
CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest CNMD
- SEC Form 4 filed by Executive Vice President & CFO Gallagher John E
- New insider Gallagher John E claimed no ownership of stock in the company (SEC Form 3)
- BMO Capital Markets initiated coverage on CONMED with a new price target
- SEC Form 4 filed by Director Martin Celine Christine
- SEC Form 4 filed by Director Mirviss Jeffrey B.
- New insider Mirviss Jeffrey B. claimed no ownership of stock in the company (SEC Form 3)
- New insider Martin Celine Christine claimed no ownership of stock in the company (SEC Form 3)
- CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026
- CONMED downgraded by BofA Securities with a new price target
- CONMED Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
Latest TMDX
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
- President & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)
- TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)